Drug repurposing: Far beyond new targets for old drugs

AAPS Journal

Volumn 14, Issue 4, 2012, Pages 759-763

  Oprea, T I ^a,b   Mestres, J ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Drug repurposing; Drug target interactions; Intellectual property; Side effect tolerance; Target identification

Indexed keywords

CELECOXIB; MEMANTINE; ROFECOXIB; THALIDOMIDE;

ALZHEIMER DISEASE; ANKYLOSING SPONDYLITIS; COLORECTAL CANCER; COLORECTAL POLYP; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG POTENCY; DRUG RECALL; DRUG REPOSITIONING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; DYSMENORRHEA; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LEPROSY; OFF LABEL DRUG USE; OSTEOARTHRITIS; PAIN; PATENT; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DESIGN; DRUG REPOSITIONING; HUMANS; INTELLECTUAL PROPERTY; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS;

EID: 84869141941     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9390-1     Document Type: Review

References (42)

1. Oprea TI. Sense and nonsense in drug discovery: a chemical perspective. In: Kruse CG, Timmerman H, editors. Towards drugs of the future. Amsterdam: IOS Press; 2008. p. 29-36.
2. Schuster D, Laggner C, Langer T. Why drugs fail-A study on side effects in new chemical entities. Curr Pharmaceut Design. 2005;11:3545-59.
3. LindsayMA. Target discovery. Nat Rev Drug Discov. 2003;2:831-8.
4. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673-83.
5. Zhao S, Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PLoS ONE. 2010;5:e11764.
6. Service RF. Surviving the blockbuster syndrome. Science. 2004;303:1796-9.
7. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006;116:2837-42.
8. Munos B. Lessons from 60 years of pharmaceutical innovation. Nature Rev Drug Discov. 2009;8:959-68.
9. Chong CR, Sullivan DJ. New uses for old drugs. Nature. 2006;448:645-6.
10. Oprea TI, Nielsen SK, Ursu O, Yang JJ, Taboureau O, Mathias SL, et al. Associating drugs, targets, clinical outcomes into an integrated network affords a new platform for computer-Aided drug repurposing. Mol Inf. 2011;30:100-11.
11. Oprea TI. Virtual screening in lead discovery: a viewpoint. Molecules. 2002;7:51-62.
12. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994;91:12013-7.
13. KurumbailRG, StevensAM,Gierse JK,Mcdonald JJ, Stegeman RA, Pak JA, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384:644-8.
14. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane Jr. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563-8.
15. Celebrex® (celecoxib) capsules package information, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d52185d-421f-4e34-8db7- f7676db2a226
16. Merck & Co., Inc. Merck announces voluntary worldwide withdrawal of Vioxx® (press release) Whitehouse Station, NJ; 2004 Sep 30.
17. Da Silva GMS, Lima LM, Fraga CAM, Sant'Anna CMR, Barreiro EJ. The molecular basis for coxib inhibition of p38a MAP kinase. Bioorg Med Chem Lett. 2005;15:3506-9.
18. PDSP (Psychoactive Drugs Screening Program) certified data, http://pdsp.med.unc.edu/pdsp.php?knowID=&kiKey=&receptorDD=& receptor=&speciesDD=&species=&sourcesDD=&source=&hot LigandDD=&hotLigand=&testLigandDD=&testFreeRadio= testFreeRadio&testLigand=celecoxib&referenceDD=&reference= &KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query
19. Weber W, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004;47:550-7.
20. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. Data completeness-The Achilles heel of drug-Target networks. Nat Biotechnol. 2008;26:983-4.
21. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008;321:263-6.
22. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462:175-81.
23. Mestres J, Seifert SA, Oprea TI. Linking pharmacology to clinical records: cyclobenzaprine and its possible association with serotonin syndrome. Clin Pharmacol Ther. 2011;90:662-5.
24. Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, et al. Drug repurposing from an academic perspective. Drug Discov Today: Therap Strategies. 2011;8:61-9.
25. Lin BK, Clyne M, Walsh M, Gomez O, Yu W, Gwinn M, et al. Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. Am J Epidemiol. 2006;164:1-4.
26. Yang JO, Hwang S, Oh J, Bhak J, Sohn T-K. An integrated database-pipeline system for studying single nucleotide polymorphisms and diseases. BMC Bioinformatics. 2008;9:S19.
27. Strachan RT, Ferrara G, Roth BL. Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discov Today. 2006;11:708-16.
28. Cases M, Mestres J. A chemogenomic approach to drug discovery: focus on cardiovascular diseases. Drug Discov Today. 2009;14:479-85.
29. Flachner B, Lörincz Z, Carotti A, Nicolotti O, Kuchipudi P, Remez N, et al. A chemocentric approach to the identification of cancer targets. PLoS ONE. 2012;7:e0035582.
30. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-52.
31. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58:409-12.
32. Wermuth CG. The 'SOSA' approach: an alternative to highthroughput screening. Med Chem Res. 2001;10:431-9.
33. Curley D, Easey A. Drug repurposing and repatenting. Bio-Science Law Review. 2009;10:131-4.
34. Sanderson K. Big interest in heavy drugs. Nature. 2009;458:269.
35. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. The topology of drug-Target interaction networks: implicit dependence on drug properties and target families. Mol BioSyst. 2009;5:1051-7.
36. Briansó F, Carrascosa MC, Oprea TI, Mestres J. Cross-pharmacology analysis of G protein-coupled receptors. Curr Top Med Chem. 2011;11:1956-63.
37. Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm Med. 2010;24:151-9.
38. Collins FS. Mining for therapeutic gold. Nature Rev Drug Discov. 2011;10:397.
39. Lipworth WL, Kerridge IH, Day RO. Wrong questions, wrong answers? Are we getting the drugs we need? Clin Pharmacol Ther. 2012;91:367-9.
40. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10:712-3.
41. Kinnings SL, Xie L, Fung KH, Jackson RM, Xie L, Bourne PE. The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol. 2010;6:e1000976.
42. Shigemizu D, Hu Z, Hung JH, Huang CL, Wang Y, Delisi C. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol. 2012;8:e1002347.